Table 3 Diastolic blood pressure level and intra-individual visit-to-visit variability in the three treatment groups during the BP measurement phase
Difference (95% CI) | P-value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Benidipine plus ARB (n=1026) | Benidipine plus BB (n=996) | Benidipine plus TD (n=991) | ARB/BB | ARB/TD | BB/TD | ARB/BB | ARB/TD | BB/TD | |
Mean, mm Hg | 78.1±7.6 | 78.0±7.8 | 78.4±8.0 | 0.15 | −0.30 | −0.44 | 0.909 | 0.668 | 0.421 |
−0.53–0.82 | −0.98–0.38 | −1.14–0.26 | |||||||
Maximum, mm Hg | 87.2±8.9 | 87.2±9.5 | 87.2±9.1 | −0.07 | −0.04 | 0.03 | 0.984 | 0.996 | 0.996 |
−0.88–0.74 | −0.82–0.75 | −0.79–0.86 | |||||||
Minimum, mm Hg | 69.3±9.1 | 69.0±9.2 | 69.8±9.2 | 0.26 | −0.51 | −0.77 | 0.799 | 0.424 | 0.149 |
−0.54–1.07 | −1.31–0.29 | −1.59–0.04 | |||||||
Maximum–minimum, mm Hg | 17.9±8.5 | 18.2±8.9 | 17.4±8.4 | 0.33 | 0.47 | 0.81 | 0.664 | 0.431 | 0.096 |
−1.10–0.43 | −0.27–1.22 | 0.04–1.57 | |||||||
Visit-to-visit variability | |||||||||
s.d., mm Hg | 6.95±3.23 | 7.06±3.36 | 6.70±3.08 | −0.11 | 0.26 | 0.37 | 0.727 | 0.167 | 0.030 |
−0.40–0.18 | −0.02–0.54 | 0.08–0.66 | |||||||
CV, % | 9.02±4.36 | 9.18±4.50 | 8.66±4.14 | −0.15 | 0.37 | 0.52 | 0.711 | 0.140 | 0.022 |
−0.54–0.24 | −0.01–0.74 | 0.14–0.90 | |||||||